Royalty Pharma (RPRX) Competitors

$54.50 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$54.46 -0.05 (-0.08%)

As of 05/22/2026 07:56 PM Eastern

RPRX vs. BMY, ZTS, JAZZ, CORT, and SUPN

Should you buy Royalty Pharma stock or one of its competitors? MarketBeat compares Royalty Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Royalty Pharma include Bristol Myers Squibb (BMY), Zoetis (ZTS), Jazz Pharmaceuticals (JAZZ), Corcept Therapeutics (CORT), and Supernus Pharmaceuticals (SUPN). These companies are all part of the "pharmaceuticals" industry.

How does Royalty Pharma compare to Bristol Myers Squibb?

Royalty Pharma (NASDAQ:RPRX) and Bristol Myers Squibb (NYSE:BMY) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, analyst recommendations, earnings, profitability, dividends and valuation.

Royalty Pharma has a net margin of 33.88% compared to Bristol Myers Squibb's net margin of 15.01%. Bristol Myers Squibb's return on equity of 64.87% beat Royalty Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Royalty Pharma	33.88%	29.25%	14.71%
Bristol Myers Squibb	15.01%	64.87%	13.16%

54.4% of Royalty Pharma shares are owned by institutional investors. Comparatively, 76.4% of Bristol Myers Squibb shares are owned by institutional investors. 18.8% of Royalty Pharma shares are owned by company insiders. Comparatively, 0.1% of Bristol Myers Squibb shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Royalty Pharma has a beta of 0.4, indicating that its stock price is 60% less volatile than the broader market. Comparatively, Bristol Myers Squibb has a beta of 0.26, indicating that its stock price is 74% less volatile than the broader market.

Royalty Pharma currently has a consensus target price of $53.71, suggesting a potential downside of 1.44%. Bristol Myers Squibb has a consensus target price of $61.31, suggesting a potential upside of 3.04%. Given Bristol Myers Squibb's higher possible upside, analysts clearly believe Bristol Myers Squibb is more favorable than Royalty Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Royalty Pharma	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	3.00
Bristol Myers Squibb	1 Sell rating(s)	10 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.37

Royalty Pharma pays an annual dividend of $0.94 per share and has a dividend yield of 1.7%. Bristol Myers Squibb pays an annual dividend of $2.52 per share and has a dividend yield of 4.2%. Royalty Pharma pays out 63.9% of its earnings in the form of a dividend. Bristol Myers Squibb pays out 70.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Royalty Pharma has raised its dividend for 5 consecutive years and Bristol Myers Squibb has raised its dividend for 17 consecutive years. Bristol Myers Squibb is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Bristol Myers Squibb has higher revenue and earnings than Royalty Pharma. Bristol Myers Squibb is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Royalty Pharma	$2.38B	13.20	$770.95M	$1.47	37.07
Bristol Myers Squibb	$48.19B	2.52	$7.05B	$3.56	16.71

In the previous week, Bristol Myers Squibb had 36 more articles in the media than Royalty Pharma. MarketBeat recorded 50 mentions for Bristol Myers Squibb and 14 mentions for Royalty Pharma. Bristol Myers Squibb's average media sentiment score of 1.28 beat Royalty Pharma's score of 0.87 indicating that Bristol Myers Squibb is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Royalty Pharma	10 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bristol Myers Squibb	40 Very Positive mention(s)	4 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Bristol Myers Squibb beats Royalty Pharma on 11 of the 19 factors compared between the two stocks.

How does Royalty Pharma compare to Zoetis?

Zoetis (NYSE:ZTS) and Royalty Pharma (NASDAQ:RPRX) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.

92.8% of Zoetis shares are held by institutional investors. Comparatively, 54.4% of Royalty Pharma shares are held by institutional investors. 0.2% of Zoetis shares are held by insiders. Comparatively, 18.8% of Royalty Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Zoetis had 18 more articles in the media than Royalty Pharma. MarketBeat recorded 32 mentions for Zoetis and 14 mentions for Royalty Pharma. Royalty Pharma's average media sentiment score of 0.87 beat Zoetis' score of 0.80 indicating that Royalty Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zoetis	21 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Royalty Pharma	10 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Zoetis currently has a consensus target price of $133.92, suggesting a potential upside of 64.81%. Royalty Pharma has a consensus target price of $53.71, suggesting a potential downside of 1.44%. Given Zoetis' higher possible upside, equities analysts plainly believe Zoetis is more favorable than Royalty Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zoetis	1 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.40
Royalty Pharma	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	3.00

Royalty Pharma has a net margin of 33.88% compared to Zoetis' net margin of 27.80%. Zoetis' return on equity of 66.85% beat Royalty Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zoetis	27.80%	66.85%	18.79%
Royalty Pharma	33.88%	29.25%	14.71%

Zoetis pays an annual dividend of $2.12 per share and has a dividend yield of 2.6%. Royalty Pharma pays an annual dividend of $0.94 per share and has a dividend yield of 1.7%. Zoetis pays out 35.2% of its earnings in the form of a dividend. Royalty Pharma pays out 63.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Zoetis has increased its dividend for 14 consecutive years and Royalty Pharma has increased its dividend for 5 consecutive years. Zoetis is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Zoetis has higher revenue and earnings than Royalty Pharma. Zoetis is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zoetis	$9.47B	3.60	$2.67B	$6.03	13.48
Royalty Pharma	$2.38B	13.20	$770.95M	$1.47	37.07

Zoetis has a beta of 0.87, indicating that its share price is 13% less volatile than the broader market. Comparatively, Royalty Pharma has a beta of 0.4, indicating that its share price is 60% less volatile than the broader market.

Summary

Zoetis beats Royalty Pharma on 12 of the 18 factors compared between the two stocks.

How does Royalty Pharma compare to Jazz Pharmaceuticals?

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Royalty Pharma (NASDAQ:RPRX) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, earnings, media sentiment, profitability, analyst recommendations, institutional ownership and valuation.

Jazz Pharmaceuticals has a beta of 0.27, suggesting that its stock price is 73% less volatile than the broader market. Comparatively, Royalty Pharma has a beta of 0.4, suggesting that its stock price is 60% less volatile than the broader market.

Jazz Pharmaceuticals presently has a consensus price target of $241.53, suggesting a potential upside of 0.71%. Royalty Pharma has a consensus price target of $53.71, suggesting a potential downside of 1.44%. Given Jazz Pharmaceuticals' higher probable upside, equities analysts plainly believe Jazz Pharmaceuticals is more favorable than Royalty Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jazz Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.84
Royalty Pharma	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, Jazz Pharmaceuticals had 5 more articles in the media than Royalty Pharma. MarketBeat recorded 19 mentions for Jazz Pharmaceuticals and 14 mentions for Royalty Pharma. Royalty Pharma's average media sentiment score of 0.87 beat Jazz Pharmaceuticals' score of 0.56 indicating that Royalty Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jazz Pharmaceuticals	4 Very Positive mention(s)	2 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Royalty Pharma	10 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Royalty Pharma has lower revenue, but higher earnings than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jazz Pharmaceuticals	$4.27B	3.53	-$356.15M	-$0.02	N/A
Royalty Pharma	$2.38B	13.20	$770.95M	$1.47	37.07

89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. Comparatively, 54.4% of Royalty Pharma shares are owned by institutional investors. 4.3% of Jazz Pharmaceuticals shares are owned by company insiders. Comparatively, 18.8% of Royalty Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Royalty Pharma has a net margin of 33.88% compared to Jazz Pharmaceuticals' net margin of 0.66%. Royalty Pharma's return on equity of 29.25% beat Jazz Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jazz Pharmaceuticals	0.66%	14.56%	5.25%
Royalty Pharma	33.88%	29.25%	14.71%

Summary

Royalty Pharma beats Jazz Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does Royalty Pharma compare to Corcept Therapeutics?

Royalty Pharma (NASDAQ:RPRX) and Corcept Therapeutics (NASDAQ:CORT) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends.

Royalty Pharma has a beta of 0.4, indicating that its share price is 60% less volatile than the broader market. Comparatively, Corcept Therapeutics has a beta of 0.36, indicating that its share price is 64% less volatile than the broader market.

54.4% of Royalty Pharma shares are owned by institutional investors. Comparatively, 93.6% of Corcept Therapeutics shares are owned by institutional investors. 18.8% of Royalty Pharma shares are owned by company insiders. Comparatively, 20.7% of Corcept Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Royalty Pharma has higher revenue and earnings than Corcept Therapeutics. Royalty Pharma is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Royalty Pharma	$2.38B	13.20	$770.95M	$1.47	37.07
Corcept Therapeutics	$761.41M	8.49	$99.65M	$0.35	172.06

In the previous week, Royalty Pharma and Royalty Pharma both had 14 articles in the media. Royalty Pharma's average media sentiment score of 0.87 beat Corcept Therapeutics' score of 0.73 indicating that Royalty Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Royalty Pharma	10 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Corcept Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Royalty Pharma presently has a consensus target price of $53.71, indicating a potential downside of 1.44%. Corcept Therapeutics has a consensus target price of $70.83, indicating a potential upside of 17.62%. Given Corcept Therapeutics' higher possible upside, analysts plainly believe Corcept Therapeutics is more favorable than Royalty Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Royalty Pharma	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	3.00
Corcept Therapeutics	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.75

Royalty Pharma has a net margin of 33.88% compared to Corcept Therapeutics' net margin of 6.14%. Royalty Pharma's return on equity of 29.25% beat Corcept Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Royalty Pharma	33.88%	29.25%	14.71%
Corcept Therapeutics	6.14%	7.40%	5.76%

Summary

Royalty Pharma beats Corcept Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Royalty Pharma compare to Supernus Pharmaceuticals?

Supernus Pharmaceuticals (NASDAQ:SUPN) and Royalty Pharma (NASDAQ:RPRX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, media sentiment, dividends, profitability and analyst recommendations.

Supernus Pharmaceuticals presently has a consensus price target of $62.17, indicating a potential upside of 28.95%. Royalty Pharma has a consensus price target of $53.71, indicating a potential downside of 1.44%. Given Supernus Pharmaceuticals' higher probable upside, research analysts clearly believe Supernus Pharmaceuticals is more favorable than Royalty Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Supernus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Royalty Pharma	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, Royalty Pharma had 11 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 14 mentions for Royalty Pharma and 3 mentions for Supernus Pharmaceuticals. Royalty Pharma's average media sentiment score of 0.87 beat Supernus Pharmaceuticals' score of 0.63 indicating that Royalty Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Supernus Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Royalty Pharma	10 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Supernus Pharmaceuticals has a beta of 0.57, meaning that its stock price is 43% less volatile than the broader market. Comparatively, Royalty Pharma has a beta of 0.4, meaning that its stock price is 60% less volatile than the broader market.

54.4% of Royalty Pharma shares are held by institutional investors. 8.8% of Supernus Pharmaceuticals shares are held by company insiders. Comparatively, 18.8% of Royalty Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Royalty Pharma has a net margin of 33.88% compared to Supernus Pharmaceuticals' net margin of -3.74%. Royalty Pharma's return on equity of 29.25% beat Supernus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Supernus Pharmaceuticals	-3.74%	13.07%	9.66%
Royalty Pharma	33.88%	29.25%	14.71%

Royalty Pharma has higher revenue and earnings than Supernus Pharmaceuticals. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Supernus Pharmaceuticals	$718.95M	3.89	-$38.55M	-$0.51	N/A
Royalty Pharma	$2.38B	13.20	$770.95M	$1.47	37.07

Summary

Royalty Pharma beats Supernus Pharmaceuticals on 14 of the 16 factors compared between the two stocks.

Get Royalty Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RPRX vs. The Competition

Export

Metric	Royalty Pharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$31.38B	$3.37B	$6.46B	$12.34B
Dividend Yield	1.72%	2.26%	2.76%	5.28%
P/E Ratio	37.08	18.74	21.21	25.65
Price / Sales	13.20	323.98	554.38	86.31
Price / Cash	11.41	125.17	43.49	56.67
Price / Book	3.16	7.09	10.37	7.14
Net Income	$770.95M	$24.45M	$3.57B	$335.98M
7 Day Performance	3.99%	6.38%	6.40%	4.15%
1 Month Performance	10.37%	2.43%	3.53%	2.54%
1 Year Performance	67.95%	62.98%	34.04%	35.06%

Royalty Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RPRX Royalty Pharma	4.0059 of 5 stars	$54.50 flat	$53.71 -1.4%	+68.0%	$31.38B	$2.38B	37.08	80
BMY Bristol Myers Squibb	4.6692 of 5 stars	$57.30 +0.5%	$61.31 +7.0%	+26.9%	$116.40B	$48.19B	16.10	32,500	Positive News
ZTS Zoetis	4.9834 of 5 stars	$77.78 +4.8%	$134.75 +73.2%	-50.1%	$31.12B	$9.47B	12.90	14,500	Dividend Announcement
JAZZ Jazz Pharmaceuticals	2.539 of 5 stars	$229.55 +0.3%	$230.56 +0.4%	+121.9%	$14.35B	$4.27B	N/A	2,890
CORT Corcept Therapeutics	3.8452 of 5 stars	$55.12 -2.2%	$70.83 +28.5%	-23.5%	$6.05B	$761.41M	157.49	300	Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RPRX) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Royalty Pharma (RPRX) Competitors

RPRX vs. BMY, ZTS, JAZZ, CORT, and SUPN

How does Royalty Pharma compare to Bristol Myers Squibb?

Summary

How does Royalty Pharma compare to Zoetis?

Summary

How does Royalty Pharma compare to Jazz Pharmaceuticals?

Summary

How does Royalty Pharma compare to Corcept Therapeutics?

Summary

How does Royalty Pharma compare to Supernus Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RPRX vs. The Competition

Royalty Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Royalty Pharma (RPRX) Competitors

RPRX vs. BMY, ZTS, JAZZ, CORT, and SUPN

How does Royalty Pharma compare to Bristol Myers Squibb?

Is RPRX or BMY more profitable?

Do institutionals and insiders hold more shares of RPRX or BMY?

Which has more volatility and risk, RPRX or BMY?

Do analysts recommend RPRX or BMY?

Is RPRX or BMY a better dividend stock?

Which has stronger valuation & earnings, RPRX or BMY?

Does the media refer more to RPRX or BMY?

Summary

How does Royalty Pharma compare to Zoetis?

Do institutionals and insiders believe in ZTS or RPRX?

Does the media refer more to ZTS or RPRX?

Do analysts rate ZTS or RPRX?

Is ZTS or RPRX more profitable?

Is ZTS or RPRX a better dividend stock?

Which has preferable earnings & valuation, ZTS or RPRX?

Which has more risk & volatility, ZTS or RPRX?

Summary

How does Royalty Pharma compare to Jazz Pharmaceuticals?

Which has more volatility & risk, JAZZ or RPRX?

Do analysts prefer JAZZ or RPRX?

Does the media refer more to JAZZ or RPRX?

Which has stronger earnings and valuation, JAZZ or RPRX?

Do institutionals & insiders hold more shares of JAZZ or RPRX?

Is JAZZ or RPRX more profitable?

Summary

How does Royalty Pharma compare to Corcept Therapeutics?

Which has more risk and volatility, RPRX or CORT?

Do insiders & institutionals believe in RPRX or CORT?

Which has preferable earnings & valuation, RPRX or CORT?

Does the media favor RPRX or CORT?

Do analysts prefer RPRX or CORT?

Is RPRX or CORT more profitable?

Summary

How does Royalty Pharma compare to Supernus Pharmaceuticals?

Do analysts prefer SUPN or RPRX?

Does the media refer more to SUPN or RPRX?

Which has more volatility and risk, SUPN or RPRX?

Do institutionals and insiders believe in SUPN or RPRX?

Is SUPN or RPRX more profitable?

Which has higher earnings and valuation, SUPN or RPRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RPRX vs. The Competition

Royalty Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools